[A20-62] Apalutamide (prostate cancer) - Addendum to Commission A20-20
Last updated 20.08.2020
Project no.:
A20-62
Commission:
Commission awarded on 28.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
| Patients with metastatic hormone-sensitive prostate cancer |
Result of dossier assessment:
| Conclusion of dossier assessment A20-20 unchanged; the inclusion of the CHAARTED study did not influence the result of the assessment. |
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-20 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-08-20: G-BA decision was published.